NasdaqGS:ALKSBiotechs
Why Alkermes (ALKS) Is Up 10.2% After Positive Phase 3 LUMRYZ Idiopathic Hypersomnia Data
On May 12, 2026, Alkermes announced positive topline Phase 3 REVITALYZ results showing that once‑nightly LUMRYZ improved excessive daytime sleepiness and other idiopathic hypersomnia symptoms versus placebo, supporting plans to file a supplemental New Drug Application with the FDA by the end of 2026.
A key nuance for investors is that, under an existing settlement, Alkermes cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028, even if it secures earlier FDA approval.
We’ll...